Rutin loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro

Paudel KR 1 , Wadhwa R 2 , Tew XN 3 , Lau NJX 3 , Madheswaran T 4 , Panneerselvam J 4 Show all authors , Zeeshan F 4 , Kumar P 5 , Gupta G 6 , Anand K 7 , Singh SK 8 , Jha NK 9 , MacLoughlin R 10 , Hansbro NG 1 , Liu G 1 , Shukla SD 11 , Mehta M 2 , Hansbro PM 12 , Chellappan DK 13 , Dua K 14

Affiliations 

  • 1 School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia
  • 2 Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia
  • 3 School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 4 Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 5 Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • 6 School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, 302017 Jaipur, India
  • 7 Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa
  • 8 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India
  • 9 Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Plot No. 32-34, Knowledge Park III, Greater Noida 201310, Uttar Pradesh, India
  • 10 Aerogen, IDA Business Park, Dangan, H91 HE94 Galway, Ireland; School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland; School of Pharmacy and Pharmaceutical Sciences, Trinity College, D02 PN40 Dublin, Ireland
  • 11 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia
  • 12 School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia. Electronic address: philip.hansbro@uts.edu.au
  • 13 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia. Electronic address: dinesh_kumar@imu.edu.my
  • 14 Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia. Electronic address: Kamal.Dua@uts.edu.au
Life Sci, 2021 Jul 01;276:119436.
PMID: 33789146 DOI: 10.1016/j.lfs.2021.119436

Abstract

Non-small cell lung cancer (NSCLC) is one of the major causes of cancer-related mortality globally. Despite the availability of therapeutic options, the improvement in patient survival is yet to be achieved. Recent advances in natural product (e.g., Rutin) research, therapeutic nanotechnology and especially the combination of both could aid in achieving significant improvements in the treatment or management of NSCLC. In this study, we explore the anti-cancer activity of Rutin-loaded liquid crystalline nanoparticles (LCNs) in an in vitro model where we have employed the A549 human lung epithelial carcinoma cell line. The anti-proliferative activity was determined by MTT and Trypan blue assays, whereas, the anti-migratory activity was evaluated by the scratch wound healing assay and a modified Boyden chamber assay. We also evaluated the anti-apoptotic activity by Annexin V-FITC staining, and the colony formation activity was studied using crystal violet staining. Here, we report that Rutin-LCNs showed promising anti-proliferative and anti-migratory activities. Furthermore, Rutin-LCNs also induced apoptosis in the A549 cells and inhibited colony formation. The findings warrant further detailed and in-depth anti-cancer mechanistic studies of Rutin-LCNs with a focus towards a potential therapeutic option for NSCLC. LCNs may help to enhance the solubility of Rutin used in the treatment of lung cancer and hence enhance the anticancer effect of Rutin.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications